In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Coronary microcirculatory function as determinator of longitudinal systolic left ventricular function in hypertrophic cardiomyopathy

Session Poster session 2

Speaker Assistant Professor Danijela Trifunovic Zamaklar

Congress : EuroEcho-Imaging 2015

  • Topic : arrhythmias and device therapy
  • Sub-topic : Hypertrophic Cardiomyopathy
  • Session type : Poster Session
  • FP Number : P594

Authors : D Trifunovic (Belgrade,RS), M Tesic (Belgrade,RS), I Jovanovic (Belgrade,RS), O Petrovic (Belgrade,RS), M Boricic-Kostic (Belgrade,RS), M Dragovic (Belgrade,RS), M Petrovic (Belgrade,RS), J Stepanovic (Belgrade,RS), M Banovic (Belgrade,RS), B Vujisic-Tesic (Belgrade,RS)

Authors:
D Trifunovic1 , M Tesic2 , I Jovanovic2 , O Petrovic2 , M Boricic-Kostic2 , M Dragovic2 , M Petrovic1 , J Stepanovic1 , M Banovic1 , B Vujisic-Tesic1 , 1Clinical Centre of Serbia, Cardiology Clinic, Medical Faculty - Belgrade - Serbia , 2Clinical Centre of Serbia, Cardiology Clinic - Belgrade - Serbia ,

Citation:
Eur Heart J Cardiovasc Imaging Abstracts Supplement ( 2015 ) 16 ( Supplement 2 ), ii88

In hypertrophic cardiomyopathy (HCM) longitudinal systolic left ventricular (LV) function is frequently depressed despite preserved LV ejection fraction and has prognostic impact.

Aim: In this echocardiographic study predictors of longitudinal LV systolic function in HCM patients were evaluated including coronary microcirculatory function assessed as coronary flow reserve (CFR) in left anterior descending coronary artery (CFR-LAD).

Methods: in 34 pts with asymmetric HCM (mean age 50 ± 15 yrs; 56% female; 8 pts with left ventricular outflow track obstruction) and 20 matched control comprehensive transthoracic echocardiographic examination was done including measurement of CFR-LAD and Vector Velocity Imaging (VVI) analysis of peak longitudinal systolic strain (S; %) and strain rate (SR; 1/s) on endocardial (endo) and epicardial (epi) level. CFR-LAD was defined as ratio between maximal velocity of coronary blood flow during diastole in rest and during maximal hyperemia induced by i.v. infusion of adenosine.

Results: HCM pts had impaired longitudinal S endo (-11.89 ± 2.78 vs -19.23 ± 3.6, p<0.001) and S epi (7.15 ± 1.93 vs 15.38 ± 3.9, p<0.001) as well as SR endo (-0.73 ± 0.17 vs -1.27 ± 0.16, p<0.001) and SR epi (-0.47 ± 0.015 vs -0.97 ± 0.19, p<0.01). CFR-LAD was significantly impaired in HCM patients (2.16 ± 0.53 vs 3.34 ± 0.67, p<0.001) and significantly correlated with S endo (r=-0.508, p=0.004), S epi (r=-0.387, p=0.035) and SR endo (r=-0.475, p=0.007). In linear regression analysis significant univariate predictors of S endo were: indexed LV mass (g/m2 BSA) (B=0.399, CI 0.003-0.053, p=0.029), indexed left atrial volume (ml/m2 BSA) (B=0.365, CI 0.003-0.171, p=0.044), ratio E/Eprim (B=0.501, CI: 0.169-0.817, p=0.004) and CFR-LAD (B=-0.508, CI:-4.137 to -0.893, p=0.004). Significant univariate predictors of SR endo were: indexed LV mass (g/m2 BSA) (B=0.434, CI 0.000-0.003, p=0.017), indexed left atrial volume (ml/m2 BSA) (B=0.354, CI 0.000-0.011, p=0.051), ratio E/Eprim (B=0.577, CI:0.017-0.055, p=0.001) and CFR-LAD (B=-0.475, CI:-0.253 to -0.044, p=0.007). In multivariate model independent predictor of S endo was CFR-LAD (B=-1.854, CI -3.644 to -0.065, p=0.043) and independent predictor of SR endo were E/Eprim (B=0.027, CI:0.006-0.047, p=0013) and CFR-LAD (B=-0.102, CI:-0.203 to 0.000, p=0.050).

Conclusion: Important determinants of impaired longitudinal LV systolic function in HCM patients are LV mass, LV filling pressure and impaired coronary microcirculatory function. Microvascular abnormalities in HCM contribute to ischemia and impaired longitudinal systolic LV function independently from other parameters.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are